Can An Omega-3 Fatty Acid Slow The Progression Of Alzheimer's Disease? Columbia Researchers Participate In Nationwide Nih Trial To Find Out.

NEW YORK (May 10, 2007) -- Nutritionists have long endorsed fish as part of a heart-healthy diet, and now some studies suggest that omega-3 fatty acids found in the oil of certain fish, algae and human breast milk may also benefit the brain by lowering the risk of Alzheimer’s disease. In order to test whether docosahexaenoic acid (DHA), an omega-3 fatty acid, can impact the progression of Alzheimer’s disease, researchers at Columbia University Medical Center, Mount Sinai School of Medicine and New York University Medical Center supported by the National Institute on Aging (NIA), part of the National Institutes of Health, will evaluate DHA in a clinical trial, the gold standard for medical research.

The local effort is part of a nationwide consortium of leading Alzheimer’s disease researchers supported by NIA and coordinated by the University of California, San Diego. The trial will take place at 51 sites across the United States. It seeks 400 participants age 50 and older with mild to moderate Alzheimer’s disease. Joseph Quinn, M.D., associate professor of neurology at Oregon Health and Science University, is directing the national study. Karen Bell, M.D. at the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain at Columbia University Medical Center, Mary Sano, Ph.D. at Mount Sinai School of Medicine and Steven Ferris, Ph.D. at New York University Medical Center will conduct the study locally.

Researchers will primarily evaluate whether taking DHA over many months slows the progression of both thinking and functional decline in people with mild to moderate Alzheimer’s. During the 18-month clinical trial, investigators will measure the progress of the disease using standard tests for functional and cognitive change.

“Evidence to date in various research studies that have examined the effect of omega-3 fatty acids on Alzheimer’s disease merits further evaluation in a rigorous clinical trial,” says Bell, Associate Clinical Professor of Neurology at Columbia University Medical Center. “Our hope is that we may find out that DHA plays a role in slowing the progression of this destructive disease.”

In recent European studies and the Framingham Heart Study, scientists reported that people with the highest blood levels of DHA were about half as likely to develop dementia as those with lower levels.

“Study volunteers will be critical to helping us find out if DHA can make an impact on the disease process,” says Sano of Mount Sinai.

For the clinical trial the Martek Biosciences Corporation of Columbia, Md., will donate a pure form of DHA made from algae devoid of fish-related contaminants. Participants will receive either two grams of DHA per day or an inactive placebo pill. An inactive placebo pill is a pill with no active medication, such as a sugar pill.

“About 60 percent of participants will receive DHA, and 40 percent will get the placebo,” explains Ferris of NYU.

Doctors and nurses at the 52 research clinic sites will monitor the participants in regular visits throughout the trial. To ensure fair results, neither the researchers conducting the trial nor the participants will know who is getting DHA and who is receiving the placebo.

In addition to monitoring disease progression through cognitive tests, researchers will also evaluate whether taking DHA supplements has a positive effect on physical and biological markers of Alzheimer’s, such as brain atrophy and proteins in blood and spinal fluid.

To learn how to participate in the study, contact the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain at Columbia University Medical Center, 212-305-7661, the Mount Sinai Alzheimer’s Disease Research Center, 212-241-1514, the Silberstein Aging Center at New York University Medical Center, 212-263-5845 or the NIA’s Alzheimer’s Disease Education and Referral Center at 1-800-438-4380 or by email to adear@nia.nih.gov. The NIA leads the federal effort that supports and conducts research on aging and the medical, social and behavioral issues of older people, including Alzheimer's disease and age-related cognitive decline. For more information visit the NIA's Alzheimer's Disease Education and Referral Center at www.nia.nih.gov/alzheimers, or call 1-800-438-4380. For general information on research and aging, go to www.nia.nih.gov and for information about NIH and its programs, visit www.nih.gov.

### Columbia University Medical Center provides international leadership in basic, pre-clinical and clinical research, in medical and health sciences education, and in patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, nurses, dentists, and public health professionals at the College of Physicians & Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. www.cumc.columbia.edu